ESMO: Blocking Angiogenesis Slows Ovarian Cancer (CME/CE)

posted on Oct 10 by MedPage Today OB/Gyn in the Uncategorized category MILAN (MedPage Today) -- Patients with advanced ovarian cancer gained about four months of progression-free survival (PFS) when treated with chemotherapy plus bevacizumab (Avastin) rather than chemotherapy alone, data from a large, randomized study showed.